We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.52% lagged the Medical sector's gain of 3.5% and outpaced the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.16, showcasing a 12.55% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.81 billion, up 0.59% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.47 per share and revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.14% higher. Gilead Sciences presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
Gilead Sciences (GILD - Free Report) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.52% lagged the Medical sector's gain of 3.5% and outpaced the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.16, showcasing a 12.55% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.81 billion, up 0.59% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.47 per share and revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.14% higher. Gilead Sciences presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.